article thumbnail

MI, HF, and Oncologic Outcomes in Breast Cancer Survivors

American College of Cardiology

Does the development of cardiovascular (CV) events, specifically myocardial infarction (MI) or heart failure (HF), in breast cancer survivors influence their oncologic outcomes?

Cancer 63
article thumbnail

Midterm outcomes of transcatheter aortic valve replacement in patients with active cancer

Open Heart

Objectives The clinical outcomes of transcatheter aortic valve replacement (TAVR) in patients with aortic stenosis (AS) and concomitant active cancer remain insufficiently explored. This study aimed to assess the midterm outcomes of TAVR in patients diagnosed with AS and active cancer. vs 74.7%, p=0.50).

article thumbnail

Esophagectomy for Cancer Risk Calculator

Society of Thoracic Surgeons - Surgeon

The esophagectomy for cancer risk calculator is powered by enhanced STS esophagectomy for cancer risk models using data from 18,503 patients across 254 hospitals between January 2015 and December 2022. Key updates include the incorporation of new risk factors such as preoperative cancer staging and body surface area.

Cancer 52
article thumbnail

Pulmonary Resection for Lung Cancer Risk Calculator

Society of Thoracic Surgeons - Surgeon

Resource Pulmonary Resection for Lung Cancer Risk Calculator gmckinney Wed, 10/16/2024 - 07:59 The new pulmonary resection for lung cancer risk calculator is engineered using contemporary data from the STS General Thoracic Surgery Database.

Cancer 52
article thumbnail

Examining apixaban vs aspirin in patients with cancer and cryptogenic stroke

Medical Xpress - Cardiology

Joseph Tarsia are co-authors on a post hoc analysis carried out in the ARCADIA randomized clinical trial, comparing the effectiveness of apixaban versus aspirin in preventing adverse clinical outcomes in patients with a history of cancer and cryptogenic stroke.

Cancer 72
article thumbnail

Abstract 4147601: Associations between Accelerated Aging Phenotypes with Cancer-Specific and Cardiovascular-Specific Mortality in Long-Term Cancer Survivorship

Circulation

Background:The consequences of cancer and anti-cancer treatments are often described as representing an “accelerated aging” phenotype. Participants missing vital data and those diagnosed with multiple cancers, childhood cancers, cancer within the previous 5 years, or skin cancer were excluded.

Cancer 40
article thumbnail

Metixene is an incomplete autophagy inducer in preclinical models of metastatic cancer and brain metastases

Journal of Clinical Investigation - Cardiology

A paucity of chemotherapeutic options for metastatic brain cancer limits patient survival and portends poor clinical outcomes. Metixene, an antiparkinsonian drug, was identified as a top therapeutic agent that was capable of decreasing cellular viability and inducing cell death across different metastatic breast cancer subtypes.

Cancer 133